Treats acute, uncomplicated influenza A and B. ANDA 209438, held by Hetero Labs Ltd Iii. Oseltamivir Phosphate.
As of Nov 16, 2026, ANDA 209438 (Oseltamivir Phosphate), held by Hetero Labs Ltd Iii, was first approved by FDA on Feb 23, 2018, with 0 approved supplements and 0 published complete response letters.
Oseltamivir phosphate is an influenza neuraminidase inhibitor (NAI) indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2018 | Original application | Approved | None posted |
| Oseltamivir PhosphateEQ 30MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
| Oseltamivir PhosphateEQ 45MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
| Oseltamivir PhosphateEQ 75MG BASE · capsule;oral | Oseltamivir Phosphate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters